logo
Plus   Neg
Share
Email

AbbVie To Buy Allergan In $63 Bln Cash, Stock Deal - Quick Facts

AbbVie Inc. (ABBV) Tuesday said it has signed a definitive transaction agreement to acquire Allergan plc (AGN) in a cash and stock transaction with an equity value of approximately $63 billion.

Under the deal terms, Allergan Shareholders will receive 0.8660 AbbVie Shares and $120.30 in cash for each Allergan Share, for a total consideration of $188.24 per Allergan Share. The total consideration is based on the closing price of AbbVie's common stock of $78.45 on June 24.

The transaction represents a 45 percent premium to the closing price of Allergan's Shares on June 24.

The acquisition is expected to be 10 percent accretive to adjusted earnings per share over the first full year following the deal closure, with peak accretion of greater than 20 percent.

AbbVie anticipates that the deal will provide annual pre-tax synergies and other cost reductions of at least $2 billion in year three.

Further, AbbVie expects to generate significant annual operating cash flow, which will support a debt reduction target of $15 to $18 billion before the end of 2021.

Following the deal closure, AbbVie Shareholders will own approximately 83 percent of the combined company, while Allergan Shareholders will own the remaining 17 percent.

The transaction is subject to conditions, including certain regulatory approvals and approval by Allergan's Shareholders.

The combined companies generated $19 billion in operating cash flow in 2018, and will have 2019 annual combined revenue of approximately $48 billion.

Upon completion of the deal, AbbVie will continue to be incorporated in Delaware as AbbVie Inc., and continue to be led by Richard Gonzalez as chairman and chief executive officer.

Allergan's two board members, including chairman and chief executive officer, Brent Saunders, will join AbbVie's Board.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products. Hundreds of Facebook employees staged a "virtual walkout" on Monday to protest the company's decision not to act on recent controversial posts by President Donald Trump on the social media platform. The employees criticized Facebook chief executive Mark Zuckerberg's decision to not moderate a post from Trump last Thursday.
Follow RTT